Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Amortization of Deferred Charges (2019 - 2021)

Historic Amortization of Deferred Charges for Protagonist Therapeutics (PTGX) over the last 3 years, with Q3 2021 value amounting to $491000.0.

  • Protagonist Therapeutics' Amortization of Deferred Charges rose 1058.56% to $491000.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $1.8 million, marking a year-over-year increase of 259.01%. This contributed to the annual value of $1.8 million for FY2020, which is 94.87% down from last year.
  • According to the latest figures from Q3 2021, Protagonist Therapeutics' Amortization of Deferred Charges is $491000.0, which was up 1058.56% from $443000.0 recorded in Q2 2021.
  • Protagonist Therapeutics' Amortization of Deferred Charges' 5-year high stood at $491000.0 during Q3 2021, with a 5-year trough of $443000.0 in Q2 2020.
  • Over the past 3 years, Protagonist Therapeutics' median Amortization of Deferred Charges value was $444000.0 (recorded in 2019), while the average stood at $449545.5.
  • Per our database at Business Quant, Protagonist Therapeutics' Amortization of Deferred Charges plummeted by 326.8% in 2020 and then soared by 1058.56% in 2021.
  • Over the past 3 years, Protagonist Therapeutics' Amortization of Deferred Charges (Quarter) stood at $445000.0 in 2019, then dropped by 0.22% to $444000.0 in 2020, then grew by 10.59% to $491000.0 in 2021.
  • Its last three reported values are $491000.0 in Q3 2021, $443000.0 for Q2 2021, and $444000.0 during Q1 2021.